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Background: Strain adaptation accompanies cross-
species transmission of prions. 
Results: Adaptation of a strain of synthetic origin 
was observed within the same host species. 
Conclusion:. When induced by recombinant PrP 
fibrils, PrPSc properties evolve over multiple serial 
passages within the same host.  
Significance:. The phenomenon of prion strain 
adaptation is more common than generally thought.   
 
SUMMARY 
 
Transmission of prions to a new host is 
frequently accompanied by strain adaptation, a 
phenomenon that involves reduction of the 
incubation period, a change in 
neuropathological features and, sometimes, 
tissue tropism.  Here we show that a strain of 
synthetic origin (SSLOW), while serially 
transmitted within the same species, displayed 
the key attributes of the strain adaptation 
process. At least four serial passages were 
required to stabilize the strain-specific SSLOW 
phenotype. The biological titration of SSLOW 
revealed a correlation between clinical signs and 
accumulation of PrPSc in brains of animals 
inoculated with high doses (10-1-10-5 diluted 
brain material), but dissociation between the two 
processes at low dose inocula (10-6-10-8 diluted 
brain material). At low doses, several 
asymptomatic animals harbored large amounts 
of PrPSc comparable to those seen in the brains 
of terminally ill animals, whereas one clinically 
ill animal had very little, if any PrPSc. In 
summary, the current study illustrates that the 
phenomenon of prion strain adaptation is more 
common than generally thought and could be 
observed upon serial transmission without 
changing the host species.  When PrPSc is seeded 
by recombinant PrP structures different from 
that of authentic PrPSc, PrPSc properties 
continued to evolve for as long as four serial 
passages. 
-------------------------------------------------------------- 
Prion diseases, or transmissible spongiform 
encephalopathies (TSEs), are a family of fatal 
infectious neurodegenerative diseases (1).  The 
infectious agent of prion disease consists of a prion 
protein in its abnormal, self-replicating, -sheet 
rich state (2).  Assistance of cofactors including 
lipids and polyanions was shown to be essential for 
converting the normal, cellular isoform of the prion 
protein, PrPC, into the highly infectious, disease-
related form, PrPSc (3,4).   
During several decades of extensive 
exploration of TSEs, our knowledge about the 
disease has been continuously shaped by the choice 
of laboratory TSE models. Among the most 
commonly used TSE models are several well-
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characterized rodent-adapted TSE strains (5). All 
currently employed rodent strains were originally 
isolated from natural TSE sources including sheep, 
goat or mink and adapted to hamsters or mice, 
sometimes via passaging through intermediate 
species (6-12).  Frequently, the original TSE 
isolates appeared to consist of strain mixtures 
(9,13-17). Nevertheless, multiple individual prion 
strains were isolated using the laborious procedure 
of cloning via limiting dilution and serial passaging 
within the same host (13,18). While several stable 
TSE strains with a broad spectrum of disease 
phenotypes were produced by adapting TSE 
isolates to rodents, the strains with short incubation 
times were preferred in the majority of subsequent 
studies as a matter of convenience.    
In recent studies, an alternative approach 
for generating TSE in rodents emerged.  This 
approach involves conversion of PrPC or 
recombinant PrP (rPrP) into PrPSc in non-seeded 
Protein Misfolding Cyclic Amplification (PMCA) 
reactions (3,4,19). When hamster PrPC was used as 
a substrate, PMCA-derived strains displayed 
disease phenotypes that closely resembled those of 
the commonly used hamster-adapted 263K or 
Hyper strains of natural origin (19,20). We 
introduced a different experimental strategy that 
does not involve PMCA, but relies on treatment of 
rPrP with chemical denaturants for converting rPrP 
into amyloid fibrils (21-25).  Using this approach a 
panel of prion strains (SSLOW, LOTSS, S05) was 
created in Syrian hamsters by inoculating fibrils 
produced in vitro from full-length rPrP (25-27). 
While recognized as a TSE infection, the disease 
produced by these strains of synthetic origin 
displayed phenotypes notably different from those 
of natural TSE strains or PMCA-derived strains. 
All synthetic strains that originated from rPrP 
fibrils were characterized by long incubation time 
to disease, slow progression of clinical disease and 
peculiar clinical and neuropathological features.  
Because no bona fide PrPSc was found in 
the preparations of rPrP fibrils, a new mechanism 
for the transmissible prion diseases referred to as 
deformed templating was proposed (26,27). 
According to this mechanism, rPrP fibrils while 
being structurally different from PrPSc, 
nevertheless, can give a rise to bona fide PrPSc via 
deformed templating. The unique disease 
phenotype expressed by the strains of synthetic 
origin supported the hypothesis that these TSEs 
originated from rPrP fibrils with unique structures.   
Considering the lessons learned from the 
cross-species adaptation of prion isolates of natural 
origin, here we asked the question of whether the 
unique disease phenotype displayed by the 
synthetic strains is stable during serial transmission 
or represents only an adaptation stage, after which a 
phenotype transforms into one of the phenotypes 
common for the TSEs of natural origin. Using 
SSLOW (Synthetic Strain Leading to OverWeight) 
(25), we found that the key SSLOW-specific 
characteristics including long incubation time to 
disease, slow progression of clinical disease, 
SSLOW-specific neurotropism and PrPSc deposition 
in the form of large subependymal plaques were all 
maintained during serial transmission. 
Unexpectedly, in a manner similar to adaptation 
that accompanies cross-species prion transmission, 
multiple serial passages were required to stabilize 
the SSLOW-specific disease phenotype despite the 
fact that transmission was conducted within the 
same species. Furthermore, the biological titration 
revealed a correlation between clinical signs and 
accumulation of PrPSc in brain at high dose inocula 
(10-1-10-5 diluted brain material), but no correlation 
between the two processes at low dose inocula (10-
6-10-8 diluted brain material). At low doses, several 
animals showed large amounts of PrPSc in the 
absence of clinical signs, whereas one clinically ill 
animal showed very small amounts of PrPSc if any. 
These results support the hypothesis that two 
distinct processes, one being responsible for PrPSc 
replication and another for accumulation of toxic 
species, exist (28). In summary, the current study 
illustrates that the phenomenon of prion strain 
adaptation is more common than previously 
thought and that it could be observed upon serial 
prion transmission without changing the host 
species. 
 
EXPERIMENTAL PROCEDURES 
Ethics statement - This study was carried 
out in strict accordance with the recommendations 
in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The 
protocol was approved by the Institutional Animal 
Care and Use Committee of the University of 
Maryland, Baltimore (Assurance Number A32000-
01; Permit Number: 0312020). 
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Bioassay - For serial transmission, 10% BHs 
prepared by sonication in PBS, pH 7.4 (25), were 
dispersed by an additional 30 sec of sonication 
immediately before inoculation. Each Syrian 
hamster received 50 l of 10% BH inoculum 
intracerebrally under 2% O2 / 4 MAC isoflurane 
anesthesia. Starting from the third month 
postinoculation, hamsters were observed daily for 
disease using a ‘blind’ scoring protocol.  Animals 
were euthanized upon reaching terminal stage or, if 
no signs of clinical disease were observed, at 685 
days post inoculation. Their brains were removed 
aseptically and saved for analysis and subsequent 
passage. End-point titration bioassay was 
performed as previously described (29). 
Proteinase K digestion - Brains were 
collected aseptically and cut in half with disposable 
scalpels. One half was used to prepare 10% BHs in 
PBS, while the second half was stored at -80C for 
future analysis or fixed in formalin for 
histopathology. Homogenization was performed on 
ice, in PBS, pH 7.4, using glass/Teflon tissue 
grinders attached to a cordless 12V compact drill 
(Ryobi). The brains were ground at low speed until 
homogeneous and stored at -80°C in 1 ml aliquots. 
For the Proteinase K digestion, 10% BH was 
diluted to 5% with the same volume of 4% sarcosyl 
in PBS, supplemented with 50 mM Tris, pH 7.5, 
and digested with 20 g/ml PK for 30 min at 37C 
with 1000 rpm shaking using a  Delfia plate shaker 
(Wallac) placed in a 37°C incubator. PK digestion 
was stopped by adding SDS sample buffer and 
heating the samples for 10 min in a boiling water 
bath. After loading onto NuPAGE 12% BisTris gels 
and transfer to PVDF membrane, PrP was detected 
with 3F4 (epitope 109-112) antibody.  
Protein misfolding cyclic amplification 
with beads - 10% NBH from healthy hamsters was 
prepared as described before (26) and used as a 
substrate for PMCA with beads (PMCAb) (30). To 
detect PrPSc in the brains of inoculated animals, 10 
µl of 10% BH were added to the 90 µl of NBH. The 
standard sonication program consisted of 30 sec 
sonication pulses delivered at 50% power 
efficiency applied every 30 min during a 24 hour 
period. For each subsequent round, 10 µl of the 
reaction from previous round were added to the 90 
µl of a fresh substrate. Each PMCAb reaction was 
carried out in the presence of three 3/32” Teflon 
beads (SmallParts #B000FMUEXG). To maintain 
the temperature during PMCAb, the microplate 
horn together with its sound enclosure was placed 
in a 37°C incubator (VWR, model 1915). For 
biochemical titrations of PrPSc in the brains of 
inoculated animals, an aliquot of 10% BH was 
sonicated within a 0.2 ml thin-wall PCR tube for 30 
sec at 50% efficiency inside microplate horn of a 
Misonix-4000 sonicator before serial log dilution 
into conversion buffer. 10 µl of each dilution were 
added to the 90 µl of NBH, and PMCAb was 
carried out as described above. To analyze PMCAb 
products, 10 l of the sample were supplemented 
with 5 l SDS and 5 l PK, to a final concentration 
of SDS and PK of 0.25 % and 50 g/ml, 
respectively, followed by incubation at 37C for 1 
hour. The digestion was terminated by addition of 
SDS-sample buffer and heating the samples for 10 
min in a boiling water bath. Samples were loaded 
onto NuPAGE 12% BisTris gels, transferred to 
PVDF membrane, and probed with 3F4 antibodies. 
Histopathological studies - Tissues from SSLOW-
inoculated hamsters were processed as described 
previously (25). Briefly, formalin fixed brain halves 
divided in the midline (from passage 2, 3, and 4) 
and spleen (from passage 2 and 4) were stained 
with hematoxylin-eosin, with monoclonal anti-PrP 
antibody 3F4 (1:1000, Covance, Berkeley, CA, 
USA) for detecting PrP, and with monoclonal anti-
glial fibrillar acidic protein (GFAP; 1:3000, Dako, 
Glostrup, Denmark). Blocks were treated in formic 
acid (96%) prior to embedding in paraffin. For 
detection of disease-associated PrP, we applied a 
pretreatment of 30 minutes hydrated autoclaving at 
121°C followed by 5 minutes in 96% formic acid. 
We evaluated all tissues for the presence of 
inflammation and PrP immunoreactivity, and the 
brain for the presence of spongiform change and 
degree of gliosis. Degree of spongiform change, 
neuronal loss and gliosis, and intensity of PrP 
immunostaining was semiquantitatively evaluated 
(0: none; 1: mild; 2: moderate; 3: severe). Lesion 
profiles were obtained by averaging scores of 
spongiform change, neuronal loss and gliosis for 
each anatomical region and animal group.  
 
RESULTS 
SSLOW maintains its strain-specific 
disease phenotype during serial transmission - To 
test whether stabilization of SSLOW-specific strain 
features requires multiple passages and to establish 
a stable disease phenotype, serial transmission of 
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SSLOW using Syrian hamsters was conducted. The 
incubation time to disease decreased from 4814 
days in the 2nd passage to 31810 days in the 3d 
(Fig. 1A). The 4th passage incubation time was not 
statistically different from that of the 3d passage, 
suggesting that it is stabilized by the 3d passage 
(Fig. 1A). This incubation time was different from 
those of currently known hamster-adapted TSE 
strains.   
In previous studies, very slow disease 
progression after the first clinical signs was 
observed for the SSLOW 2nd passage (25). In a 
similar manner, the animals of the 3d and 4th 
passages also showed very slow progression of 
symptoms (Fig. 1A).  The clinical stage lasted for 
approximately 90 to 150 days after disease onset 
before reaching a terminal stage. The first 
indication of clinical onset was a non-habituating 
startle response to sound and touch and an agitated, 
fidgeting behavior. As disease progressed, animals 
were unable to rear unassisted by a cage wall and 
had increasing difficulty righting themselves when 
rolled onto their back. During the progression, the 
hair became very dry standing out from the body 
and could be easily detached in large clumps even 
with gentle handling. By the terminal stage, the 
animals had become less active in general, and 
when active their movements were much slower. 
Overall, serial transmission of SSLOW revealed 
that strain-specific clinical features were preserved 
and that long incubation time to onset and very 
slow disease progression represents the clinical 
hallmark of this strain.  
As reported previously (25), obesity was 
one of the most notable clinical features of 
SSLOW-infected animals. Consistent with previous 
observations, the majority of animals from the 3d 
passage weighted significantly more than that of a 
control group by 300 days postinoculation (Fig 1B). 
Although other clinical signs were not yet 
detectable at this time point, weight gain alone 
might not serve as a reliable early marker of the 
clinical disease, because a small fraction of 
SSLOW-inoculated animals have never gained a 
weigh higher than that of a control group. 
Nevertheless, regardless of whether SSLOW-
inoculated animals were overweight or not, they 
showed substantial weight fluctuation during 
clinical disease, while the weight of individual 
animals within age-matched control group 
remained stable.  
Histopathological study revealed gradual 
stabilization of SSLOW-specific features - As 
judged from the lesion profile and PrP 
immunoreactivity score, animals from the 2nd, 3d 
and 4th passages exhibited similar 
neuropathological features (Fig. 2 A,B). These 
features, however, continued to evolve for as far as 
the 4th passage.  In SSLOW-inoculated animals 
from the 2nd, 3d and 4th passages, the spongiform 
changes, neuronal loss, and reactive astrogliosis 
were prominent in the thalamus, caudate-putamen, 
brainstem, and deeper layers of the cerebral cortex, 
but relatively mild in the hippocampus and 
cerebellum (Fig. 2 A). However, the 4th passage 
animals exhibited more substantial lesions in the 
cerebellar granular layer than animals of the 2nd and 
3d passages. (Fig. 2 A). The region-specific PrP 
deposition profile was similar in animals from all 
three passages and consisted of synaptic and 
perineuronal deposits, as well as large plaques of 
25-60 m size in the subependymal regions (Fig. 2 
B, I-N).  Again, 4th passage animals exhibited 
substantially more prominent PrP deposition in 
most areas including the cerebellum, thalamus, and 
hippocampus than those of the 2nd or 3d passages 
(Fig. 2B-K).  Moreover, while animals from the 2nd 
and 3d passages showed significant variations in the 
intensity of deposition within the same animal 
group, the animals from the 4th passage showed 
very uniform PrP immunoreactivity between 
animals (Fig. 2 B).  
Previously we did not observe any signs of 
PrP deposition in spleens in the animals of the 2nd 
passage that led us to conclude that SSLOW is not 
lymphotrophic. Surprisingly, small amounts of PrP 
immunodeposition were found in the spleens of 4th 
passage animals (Fig. 2 O,P). These experiments 
demonstrated that SSLOW histopathological 
features including a tropism to lymphoid tissues 
continue to evolve during serial transmission even 
after the incubation time to disease has stabilized.  
SSLOW-specific dose dependence - To 
establish a SSLOW-specific dose-response curve, 
two ten-fold serial dilutions were prepared using 
BHs of two terminally sick animals from the 2nd 
passage and each dilution was inoculated into a 
group of four animals. For the animals inoculated 
with high doses (10- to 104-fold diluted BH), the 
incubation period to the initial clinical signs 
showed a very modest increase with serial dilution 
(Fig. 3A,B). However, the progression to a terminal 
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stage after the first signs was much slower for the 
animals inoculated with low doses (Fig. 3B). The 
animals inoculated with 105-fold and higher 
dilutions showed a much stronger dose dependence 
of incubation time to disease (Fig. 3). An 
incomplete attack rate was observed for 106- and 
107-fold dilutions, while no animals inoculated with 
108-fold or higher dilutions showed clinical signs 
(Table 1). A point of inflection, which is normally 
observed in the end-point titration experiments 
(31), occurred between 104 and 105-fold dilutions.    
To test whether any asymptomatic animals 
inoculated with low doses were infected, Western 
blot and serial PMCAb (sPMCAb) were employed 
to detect PrPSc in their brains. Six PrPSc-positive 
brains were identified by Western blot in a group of 
asymptomatic animals that were inoculated with 
106-, 107- or 108-fold diluted brain material (Fig. 4, 
Table 1). On the other hand, one animal (# 366) 
that was clinically ill showed a barely visible, if any 
at all, signal on Western blot (Fig. 4 and 6).  
Furthermore, brains from an additional seven 
asymptomatic animals that were negative on 
Western blot were found to contain small amounts 
of PrPSc in experiments where their brain material 
was used to seed PrPSc amplification in sPMCAb 
consisted of three rounds (Fig. 5, Table 1). 
sPMCAb seeded with BHs from age-matched 
controls were used in each sPMCAb experiments 
and were always negative (data not shown). These 
results illustrate that (i) inoculations with low doses 
could lead to subclinical prion infection and (ii) 
asymptomatic animals might harbor various 
amounts of PrPSc, from as large as typically found 
in the terminally ill animals to as little as those that 
could only be detected by sPMCAb. 
Dissociation between clinical disease and 
amounts of PrPSc in animals inoculated with low-
dose inocula - At the high dose inocula (from 10 to 
105 -fold diluted BHs), all animals developed 
clinical disease and showed large amounts of PrPSc 
in their brains. The result illustrates a nice 
correlation between accumulation of PrPSc and 
occurrence of clinical signs.  In contrast, in animals 
inoculated with the low doses (from 106- to 108-fold 
diluted BH), a dissociation between PrPSc amounts 
in brains and clinical status was observed. On one 
hand, several animals (# 313, 314, 317, 357 and 
359) harbored PrPSc in amounts comparable to 
those seen in brains of terminally ill animals, yet 
remained asymptomatic (Fig. 4). On the other hand, 
one animal (# 366) was found to be clinically ill, 
but had very little if any PrPSc, as judged by 
Western blot (Fig. 4, 6). Together, these results 
revealed a lack of correlation between PrPSc 
amounts and the clinical status in animals 
inoculated with the low doses.  
To test whether PrPSc from the animal #366 
was intrinsically more sensitive to PK digestion 
than PrPSc from other brains, BHs were treated with 
a broad range of PK concentrations. Surprisingly, at 
low PK concentrations the PK-resistant signal did 
not increase (Fig. 6). This result supports the notion 
that the animal #366 harbored very small amounts 
of PK-resistant PrPSc rather than PK-sensitive PrPSc.  
To test whether clinical status correlates 
with the number of PMCAb-reactive PrPSc 
particles, BHs from the animal #365 (symptomatic, 
large amounts of PrPSc), #366 (symptomatic, 
miniscule amounts of PrPSc) and #317 
(asymptomatic, large amounts of PrPSc) were 
subjected to PMCAb titration as previously 
described (29). BHs were serially diluted 10-fold 
up to 1013-fold, and each dilution was used to seed 
sPMCAb.  In sPMCAb consisting of three serial 
rounds, the reactions seeded with as high as 1010-
fold and 109-fold diluted BHs #365 and #317, 
respectively, were positive (Fig. 7A). Surprisingly, 
sPMCAb reactions seeded with 104- to 1013-fold 
diluted brain material from animal #366 were all 
negative (Fig. 7A). To test whether the brain #366 
contained any PMCAb reactive material at all, the 
reactions were seeded with a series of low dilutions. 
No amplification was detected in reactions seeded 
with brain material #366 diluted 103-fold or higher 
in sPMCAb consisting of three rounds (Fig 7B). In 
comparison, the reactions seeded with 104- and 105-
fold diluted brain materials from animal #365 or 
#317 were positive after the first and second 
rounds, respectively. These experiments showed 
that brain #366 had very small amounts of PMCAb 
reactive material and/or that, in contrast to PrPSc 
from the rest of SSLOW-inoculated animals, PrPSc 
from #366 is not readily amplifiable by PMCAb.  
 
DISCUSSION  
In previous studies we reported that 
transmissible prion disease could be generated in 
Syrian hamsters upon inoculation of amyloid fibrils 
prepared in vitro from full-length recombinant PrP 
(25-27). While rPrP fibrils displayed very limited 
infectivity, the prion disease that emerged in the 
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second or third passages showed very unique 
phenotypes. This was significantly different from 
other approaches for generating prion disease de 
novo that involved conversion of PrPC or rPrP into 
PrPSc in non-seeded PMCA supplemented with 
brain homogenate or cellular cofactors (3,4,19). 
Because PrPSc generated in PMCA reactions with 
hamster PrPC produced disease phenotypes similar 
to those of two of the most commonly employed 
hamster-adapted prion strains, 263K and Hyper 
(19,20), it was proposed that hamster PrP displays a 
natural tendency to adopt 263K- or Hyper-specific 
PrPSc folding pattern (20).  The question of great 
interest is whether the unique disease phenotype 
that emerged upon fibril inoculation in our studies 
is sustainable in a serial transmission or transforms 
into a phenotype specific for one of the existing 
hamster-adapted strains.  If the latter is true, the 
unique features observed for SSLOW 2nd passage 
would have to be interpreted as a stage in the 
evolution of a more stable strain-specific 
phenotype.  
To address this question, serial 
transmission of SSLOW was performed. The 
incubation time reduced from 4855 days at the 2nd 
passage to 31816 days at the 3d passage but did 
not show any further drop at the 4th passage. This 
result argues that the incubation time to disease is 
stabilized by the 3d passage and that SSLOW is 
characterized by an intrinsically long incubation 
time which is different from those of known 
hamster-adapted strains (5). Furthermore, 
regardless of a serial passage number SSLOW-
infected animals consistently showed very slow 
progression of clinical disease.  While the duration 
of a clinical stage varied in individual animals from 
~90 to 150 days, the mean duration remained stable 
during serial passages (Fig. 1A). An alternative 
explanation for a slow disease progression is that in 
SSLOW-inoculated animals the first noticeable 
clinical signs were observed at an earlier disease 
stage than in animals inoculated with experimental 
rodent-adapted strains. Nevertheless, the long 
incubation time to the terminal stage supports the 
previous conclusion that rPrP fibrils produce 
unique disease phenotypes.  
A number of pathogenic features including 
long incubation time to and duration of clinical 
disease and weight gain were found to be peculiar 
for SSLOW. Obesity was previously reported in 
animals inoculated with 139H hamster-adapted 
scrapie agent (32). However, unlike 139H, in 
addition to overall weight gain SSLOW-inoculated 
animals exhibited significant individual weight 
fluctuation during the clinical stage (Fig. 1B). 
Moreover, a fraction of SSLOW-inoculated animals 
never gained weight above the control group or 
showed substantial weight loss after weight gain. 
These results suggest that the mechanism behind 
prion-induced impairment in energy homeostasis in 
SSLOW and 139H is different. Furthermore, 
SSLOW- and 139H-specific PrPSc display 
dramatically different amplification efficiencies in 
PMCAb. 139H PrPSc is characterized by a very 
poor amplification rate (5,33), whereas the 
amplification rate of SSLOW PrPSc was found to be 
almost as high as that of 263K PrPSc (30,33). In 
summary, the current studies demonstrated that 
rPrP fibrils produced a unique disease phenotype, 
and that its unique features were preserved during 
serial transmission.   
Surprisingly, while the incubation time was 
found to stabilize at the 3d passage, the 
histopathological assays revealed a notable increase 
in intensity of PrP deposition in most brain areas in 
animals of the 4th passage comparing to those of the 
3d passage. Furthermore, PrP immunoreactivity was 
observed in spleens of animals from the 4th passage. 
While all currently known hamster-adapted strains 
target lymphoid tissues, PrP immunoreactivity was 
not detected in animals from the SSLOW 2nd 
passage (25).  These results suggest that PrPSc 
properties continue to evolve for as far as four 
serial passages and that PrPSc invasion of brain 
regions and peripheral tissues become more rapid 
and/or more aggressive with serial transmission. 
Previously, upon transmission and adaptation of 
prions to a new host, lymphoid tissues were found 
to be more permissive than brain to prion 
replication (34). Opposite to the high susceptibility 
of lymphoid tissues to prion invasion upon cross-
species transmission, the current study shows that 
lymphotropism emerged much later when a new 
strain evolved within the same host. It is possible, 
however, that the initial lack of lymphotropism was 
a reflection of an inoculation route. Because rPrP 
fibrils were first exposed to brain tissues, the newly 
emerged PrPSc population was set to adapt to a 
brain environment. We do not know whether the 
initial tissue tropism would be different if 
peripheral inoculation routes were used.    
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Gradual change in strain properties 
including neurotropism are frequently observed 
upon cross-species prion transmission in a 
phenomenon referred to as strain adaptation 
(6,7,15,35). The process of strain adaptation to a 
new host can occur for several serial passages and 
is attributed in large part to adaptation of the strain-
specific structure of donor PrPSc to the amino acid 
sequence of the acceptor PrPC. In a manner similar 
to strain adaptation, several serial passages were 
required to stabilize SSLOW-specific features in 
the current study. However, in contrast to an 
adaptation that accompanies cross-species 
transmission, the process of SSLOW ‘adaptation’ 
was observed in the absence of changing the host  
species.  
The current study illustrates that the 
phenomenon of prion strain adaptation is more 
common than has been generally thought. It could 
be observed upon serial prion transmission within 
the same host and in the absence of changes in the 
PrP amino acid sequence or prion replication 
environment. Presumably, the adaptation within the 
same host was at7tributed to the fact that rPrP 
amyloid fibrils that give rise to synthetic strains 
display a folding pattern substantially different 
from those observed in PrPSc. Because replication 
of rPrP amyloid structure is cofactor independent, 
whereas replication of PrPSc is co-factor dependent 
(33,36,37), adaptation could also be attributable to  
transformation of cofactor independent to cofactor 
dependent self-replicating PrP structures. The last 
hypothesis seems particularly attractive considering 
recent data that cellular cofactors including lipids 
might play an active role in defining strain-specific 
features (38,39). The adaptation of synthetic strains 
within the same host was likely to involve a 
selection and evolution of a PrPSc subpopulation 
that was best suited to replicate in a particular 
cellular environment, such as the brain or lymphoid 
tissues. 
In transmissible prion diseases, the 
incubation time to disease correlates with the 
inoculated dose in a predictable manner (40,41). In 
the current studies, animals inoculated with high 
doses of SSLOW showed a very modest dose-
dependence for the incubation time to disease (Fig. 
3B). In fact, the incubation time was not 
statistically different between the four groups that 
received 10-, 102-, 103- or 104-fold diluted SSLOW 
BHs (Fig. 3A,B).  However, the mean duration of 
clinical stage increased significantly with serial 
dilution of inocula (Fig. 3B). If a total time to 
terminal stage is used instead of the incubation time 
to initial clinical signs, SSLOW titration followed a 
dose-response relationship typically observed in 
titration experiments. Noteworthy, an increase in 
duration of clinical stage as a function of inoculum 
dose was previously reported for other rodent 
strains including RML (41). We do not know 
whether the long time between first signs and 
terminal stage in SSLOW-inoculated animals could 
be attributed to the intrinsically slow progression of 
the clinical stage or to the possibility that the first 
noticeable signs of the disease are detectable at 
much earlier stages than in animals infected with 
other TSE strains. 
If clinical signs were used as a sole read-
out parameter for estimating infectivity titer, 106-
fold diluted SSLOW brain material corresponded to 
a limiting dilution at which only 50% of animals 
developed the disease (Table 1). In agreement with 
the dose-response curves reported for other TSE 
strains (31), an inflection point occurred at 
approximately 102 units of infectivity above the 
limiting dilution established by clinical criteria. The 
physical basis for the inflection point in a dose-
response curve remains unclear. Upon intracerebral 
inoculation, only a small fraction of infectious 
material appears to settle down in the brain, while a 
significant part of it either cleared or moved out 
from the brain into peripheral organs and tissues 
(42). One can speculate that at low inoculum doses, 
the brain is not infected immediately, but rather 
after prions leave the brain, infect peripheral 
organs, and then re-invade the central nervous 
system. If this mechanism is correct, it explains the 
prolonged incubation time and stochastic scattering 
of individual incubation times observed at low 
doses. As an indirect support of this mechanism, 
recent studies revealed that following cross-species 
intracerebral inoculations, prions were found to 
replicate more effectively in lymphoid tissues than 
in brain (34).   
In agreement with previous studies 
(29,41,43), the current work revealed that the 
infectivity titer is likely to be underestimated if 
appearance of clinical signs is used as sole read-out 
parameter. Indeed, upon application of Western 
blot and sPMCAb, substantial fractions of animals 
inoculated with 106- to 108-fold diluted brain 
material were found to be infected without 
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displaying any clinical signs (Table 1). In fact, 
sPMCAb improved prion detection limits in 
animals inoculated with low doses by 
approximately 102-fold beyond the limiting dilution 
established by occurrence of clinical signs. 
Detection of PrPSc by PMCAb revealed that 
animals inoculated with small doses represent 
asymptomatic prion carriers for the animals’ 
lifetime. Notably, this result resembled persistent 
prion infections observed in the absence of clinical 
signs upon cross-species transmission (44-46). 
However, in contrast to the low inocula doses that 
gave rise to subclinical SSLOW infection, high 
dose inocula were used in inter-species 
transmission experiments. Considering that the half 
life of PrPSc is relatively short (42,47), it is unlikely 
that SSLOW PrPSc detected by sPMCAb at more 
than 600 days postinoculation represents the 
original material inoculated at high dilutions. 
Notably, the asymptomatic animals showed 
significant variations in the amounts of PrPSc. 
Taken together, these results highlight the 
stochastic nature of events leading to PrPSc 
replication and accumulation at low inocula doses.  
100% of animals inoculated with high 
doses (10- to 105-fold diluted BHs) were found to 
harbor large amounts of PrPSc and develop prion 
disease. However, at the low doses (106- to 108-fold 
diluted BHs), large amounts of PrPSc were observed 
in the absence of clinical signs in several animals, 
whereas one symptomatic animal had very little, if 
any PrPSc. It is likely that animals inoculated with 
the low doses require longer time to reach a toxic 
threshold to trigger clinical stage. Therefore, these 
results might suggest that old animals are less 
susceptible to PrPSc toxicity or need a higher PrPSc 
threshold. These data might also suggest that only a 
small sub-fraction of PrPSc is neurotoxic. In 
SSLOW-infected animals, a substantial fraction of 
PrPSc is deposited in the form of large plaques 
suggesting that large deposits are less toxic to 
neurons than small, diffuse deposits. Nevertheless, 
the current work supports the hypothesis that two 
distinct processes, one being responsible for PrPSc 
replication and another for accumulation of toxic 
species, exist (28). While accumulation of toxic PrP 
species was tightly coupled to PrPSc replication in 
animals inoculated with high doses, these two 
processes appear to be in disarray at the low dose 
inocula. It is unclear whether toxic PrP species are 
intermediate or byproducts of PrPSc replication, or 
whether they are catalyzed by or formed 
independently of PrPSc.  
One of the most intriguing results of the 
current study was an observation of a very small 
PrPSc amount in the clinically ill animal #366. Even 
a substantial decrease in PK concentration did not 
lead to a higher PrPSc signal on Western blot for 
this animal. Furthermore, a series of PMCAb 
experiments revealed that the brain #366 contained 
very low titers of PMCAb reactive material and/or 
that the PrPSc harbored in the brain #366 was not 
readily amplified in PMCAb, unlike PrPSc from 
other SSLOW-inoculated animals. On the other 
hand, a high titer of PMCAb-reactive material was 
found in an asymptomatic brain (animal #317). 
Again, these results support the hypothesis that the 
two processes, one leading to accumulation of 
PMCAb-reactive material or PrPSc and another to 
accumulation of toxic PrP species are distinct and 
dissociated.  An alternative possibility to consider 
for explaining the puzzle with the animal #366 is 
that serial passage of SSLOW at a low dose 
resulted in an isolation of a new strain. In previous 
studies, serial passages of TSE agents at high and 
low doses often produced two different strains, a 
phenomenon referred to as strain breakdown or 
mutation (9,13,15,16,18). Typically, strain 
breakdown was observed upon cross-species 
transmission and adaptation to a new host 
(9,13,15,18). Nevertheless, consistent with the 
hypothesis that prion strains consist of quasi-
species (48,49), prion replication in a new cellular 
environment might lead to isolation of a new strain 
that was present in small amounts in the original 
inoculums.  One could speculate that inoculation of 
rPrP fibrils resulted in a mixture of PrPSc 
conformations in animal brain, from which distinct 
strains are selected depending on inocula dose in 
the course of serial passages. Changes in the 
physical properties of PrPSc populations during 
serial transmission are consistent with this 
hypothesis (23,25,50).  Nevertheless, it remains to 
be determined in future studies whether the animal 
#366 harbors a strain different from SSLOW. 
While infectivity of rPrP fibrils generated 
in vitro was very low, peculiar conformation of 
rPrP fibrils gave rise to a panel of new prion strains 
including SSLOW and LOTSS with unique disease 
phenotypes (25-27). These new strains of synthetic 
origin represent valuable new models of TSE 
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disease, which are worth of exploiting for 
addressing a number of questions in prion biology.  
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Table 1. Comparison of the titration results for low dose inocula 
Inoculum 
dilution 
Clinical TSE / 
total inoculated  
Positive in Western blot 
/ total inoculated 
Positive in sPMCAba / 
total inoculated 
10-5 5/5b 5/5 5/5 
10-6 4/8 5/8 7/8c 
10-7 1/8 4/8 8/8 
10-8 0/8 1/8 2/8 
a The results are based on appearance of PK-resistant positive signal after three sPMCAb rounds 
b Three animals from this group succumbed to unrelated illness. 
c One out of seven BHs with positive PMCAb seeding activity showed very low amplification 
rate. 
 
FIGURE LEGENDS 
 
Figure 1. Serial transmission of SSLOW. (A) Mean incubation time to disease onset (light gray 
bars) and mean duration of clinical stage after the appearance of first clinical signs (dark gray 
bars) as a function of SSLOW serial passage. (B)  Change in body weight during the clinical 
stage in individual animals inoculated with 10% SSLOW BH (thin red lines) or with 1011-fold 
diluted SSLOW BH used as a control group (thick black lines). No animals inoculated with 1011-
fold diluted BH showed clinical signs or PrPSc in their brain material. The results are from the 3d 
SSLOW passage.  
Figure 2. Histopathological analysis. (A) Lesion profile obtained by averaging scores of 
spongiform change, neuronal loss and gliosis, and (B) PrP immunopositivity score for each 
anatomical region in hamsters of the 2nd, 3d, and 4th SSLOW passages. The lesion profile was 
obtained by averaging the scores for spongiform change, neuronal loss, and gliosis for three 
animals within each group. Overview (x250) of the hippocampus (C-E), thalamus (F-H), 
cerebellum (I-K), and subependymal region (L-N) using immunostaining for disease-associated 
PrP in animals from the 2nd (C, F, I, L), 3d (D, G, J, M), or 4th (E, H, K, N) SSLOW passages. 
High magnification (x400) images of PrP immunostaining in the spleen (O, P) in animals from 
the 2nd (O) and 4th (P) SSLOW passages. Scale bar 15 m in C-E and I-K, 25 m in F-H and L-
N, and 10 m in O, P. 
Figure 3. Relationship between inoculation dose and incubation time. (A) Incubation time to 
disease as a function of inoculum dose for two independent serial dilutions (shown as triangles 
and circles) prepared from brain material from two animals from 2nd passage of SSLOW. Each 
serial dilution was inoculated into a group of four animals for each titration experiment.  Dashed 
line indicates an inflection point.  (B) Mean incubation time to disease onset (light gray bars) and 
mean duration of the clinical stage of the disease after the first symptoms (dark gray bars) as a 
function of inoculum dose for two independent serial dilutions. Three animals in these group 
marked by asterisk succumbed to illnesses not related to TSE.  
Figure 4. Western blot analysis of PrPSc in animals ioculated with low doses. Western blot of 
BHs from animals of SSLOW 3d passage inoculated with 104- to 108-fold diluted BHs as 
indicated. N marks animals that did not show any clinical signs, and C marks animals that 
progressed to clinical stage. Asymtomatic animals were euthanized at 685 dpi. Samples were 
threated with 20 µg/ml PK, 3F4 antibody was used for staining.  
Figure 5. Detection of PrPSc in animals ioculated with low doses using PMCAb. Western 
blots of products of sPMCAb reactions seeded with BHs from the animals of SSLOW 3d passage 
inoculated with 106 -, 107- or 108-fold diluted BHs as indicated. sPMCAb consisted of three 
rounds, 3F4 antibody was used for staining. 
Figure 6. Analysis of PrPSc resistance to PK. BHs from animals inoculated with 106-fold 
diluted BHs were treated with increasing concentration of glycerol-free PK as indicated for 1 
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 12
hour at 37°C. N marks animals that did not show any clinical signs, and C marks animals that 
progressed to clinical stage. Western blots were stained with 3F4.  
Figure 7. Analysis of PMCAb-reactive material. (A) PMCAb titration of BHs from animals 
inoculated with 106-fold diluted BHs. BHs from animals # 365, 366 or 317 were serially diluted 
up to 1013-fold into 10% NBH as indicated and subjected to four sPMCAb rounds. Nine non-
seeded control sPMCAb reactions are shown. (B) BHs from animals # 365, 366 or 317 were 
serially diluted up to 105-fold into 10% NBH as indicated and subjected to one, two or three 
sPMCAb rounds. Undigested 10% NBH is provided as a reference (-PK). Western blots were 
stained with 3F4. 
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